News Releases
- Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 22, 2020
- Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 16, 2020
- Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 September 2, 2020
- Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD August 25, 2020
- Algernon Updates Market on Analyst Coverage by Mackie Research August 24, 2020
- Algernon Announces Research Analyst Coverage by Mackie Research with an $0.80/share Target Price August 24, 2020
- Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD August 17, 2020
- Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 August 13, 2020
- Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 August 5, 2020
- Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil August 5, 2020